Telehealth Platform With Subscription Management (2026)

A telehealth platform with subscription management should connect a branded storefront to clinical review, pharmacy routing, recurring billing, refills, cancellations, and compliance records. The strongest evaluation focuses on the complete operating system—not just the checkout page or video visit—and tests whether the vendor can support state-specific workflows without automating clinical judgment.

What is different about evaluating a telehealth platform with subscription management?

A general telehealth platform may be judged on scheduling, video, documentation, and messaging. A subscription-based direct-to-consumer operation adds a second clock: the billing and fulfillment cycle continues after the initial encounter.

That means the platform must coordinate:

• A custom domain, branded storefront, service pages, disclosures, and analytics.
• Patient location, identity, consent, licensure routing, clinical intake, and escalation.
• Clinician authorization before a prescription or refill proceeds.
• Pharmacy or compounder identification and routing.
• Recurring charges, failed payments, skips, pauses, refunds, renewal notices, and cancellations.
• Exportable records showing what the customer accepted, when they accepted it, and what happened afterward.

A subscription is therefore not permission to automatically renew a prescription. The platform may run the commercial and administrative operation, while independently licensed clinicians make every clinical decision. MDLaunchr is one of the platforms in this category; buyers should apply the same questions and evidence requirements to it that they apply to any other vendor.

Weighted evaluation criteria for a white-label telehealth storefront

Use the following 100-point framework with every vendor under consideration. The weighting reflects the risks specific to recurring telehealth—not a claim that any vendor is objectively superior.

The highest-weighted areas are clinical governance and recurring operations. A visually polished custom storefront should not score well if it can charge a customer after a clinician declines treatment, renew a prescription without required authorization, or make cancellation harder than enrollment.

What should a custom telehealth storefront include?

A white label telehealth storefront should do more than display a logo and color palette. At minimum, ask whether it can publish clearly separated service, membership, pharmacy, shipping, lab, and clinical-fee information.

The checkout should show the recurring price, billing interval, promotional or trial expiration when applicable, and cancellation method before payment information is collected. It should retain evidence of express consent and produce a confirmation when a customer cancels.

The operational test should include these scenarios:

1. 1A customer enrolls but does not receive a prescription after clinical review.
2. 2A clinician needs additional information before a decision.
3. 3A refill is not clinically authorized by the expected date.
4. 4A payment fails before fulfillment.
5. 5A customer pauses, skips, changes refill timing, or cancels.
6. 6A customer requests a refund after a charge but before fulfillment.
7. 7A customer moves to a different state.
8. 8A product page needs to distinguish an FDA-approved product from a compounded drug.

The FTC’s subscription materials emphasize clear material terms, consumer consent, and a simple way to stop recurring charges. The Restore Online Shoppers’ Confidence Act also addresses disclosure, express informed consent, and stopping recurring charges. The FTC’s 2024 amended “click-to-cancel” rule is not currently in force: the Eighth Circuit vacated it on July 8, 2025, and a March 11, 2026 advance notice of proposed rulemaking is only a proposal. That does not remove the need for a straightforward cancellation process or make current legal review unnecessary.

Can telehealth platforms manage prescription refills?

They can support refill administration, but software should not silently convert a subscription into automatic prescribing. The platform should show where a licensed clinician reviews the request, what authorization is required, how the pharmacy receives the order, and how the patient is notified when the expected timeline changes.

Request a test that follows one refill from customer request through clinician review, authorization, pharmacy routing, messaging, billing, and record retention. Ask whether the system can stop a charge when clinical review does not result in a prescription or when fulfillment cannot occur.

Pharmacy transparency is also part of the storefront. FDA states that compounded drugs are not FDA-approved, and its March 3, 2026 announcement described warning letters involving allegedly misleading compounded GLP-1 marketing. Product pages and marketing workflows should identify product status accurately, identify the actual pharmacy or compounder where required, and flag claims that suggest a compounded product is the same as, generic to, or FDA-approved in the manner of a different product.

For a deeper diligence step, use this pharmacy network credentialing checklist alongside the platform demonstration.

How should a platform handle state-specific workflows?

A national storefront still needs configurable state logic. HHS identifies patient location, provider licensure, consent, possible pre-existing-relationship requirements, and prescribing rules as DTC telehealth considerations; no single national workflow should be assumed.

Examples illustrate why the rules engine matters:

• California: The Medical Board states that physicians treating patients located in California must hold a California license, and the standard of care remains the same as for in-person care. Telehealth consent may be verbal or written, but it must be documented. California DHCS describes additional modality and consent distinctions in the Medi-Cal context, including limits on establishing new relationships through synchronous audio-only care except in specified circumstances.
• Texas: Texas law permits a practitioner-patient relationship to be established through a compliant audiovisual telemedicine encounter when statutory requirements and the standard of care are met. The platform still needs informed-consent, licensure, and delegation or supervision workflows where applicable.
• Florida: Florida’s telehealth statute includes a telehealth evaluation pathway but separately restricts Schedule II controlled-substance prescribing through telehealth, subject to listed exceptions. A general “clinician approved” pathway is not enough for every medication category.
• New York: New York Department of Health guidance raises corporate-practice and entity-structure concerns for unauthorized corporations arranging professional services. Ownership, professional-entity structure, management agreements, revenue flows, and clinical control need a state-specific review before launch.

These examples are not a nationwide rule. A founder should have the proposed clinical model, entity structure, and subscription workflow reviewed by appropriate healthcare counsel and clinical leadership before launch.

The DEA and HHS extended current telemedicine flexibilities for prescribing controlled medications through December 31, 2026, subject to the temporary rule, DEA requirements, and state law. A platform evaluated in 2026 should support modality controls, practitioner verification, state restrictions, documentation of the authority used, and alerts before that expiration date. It should not present the temporary extension as permanent or as permission for every medication and state.

Questions to ask before you sign

Send these questions to each vendor and request written answers or a live demonstration.

Clinical operations

1. 1“Where in the workflow does an independently licensed clinician review an initial request and each refill?”
2. 2“Can the system prevent an automatic refill or charge when clinical review is incomplete, declined, or no longer appropriate?”
3. 3“How do you capture patient location, provider eligibility, state-specific consent, escalation, and in-person referral records?”

Pharmacy and products

1. 1“How does the storefront identify the actual dispensing pharmacy or compounder and distinguish FDA-approved from compounded products?”
2. 2“Can I test a refill from clinician authorization through pharmacy routing, patient messaging, billing, and record export?”

Data and security

1. 1“Will you sign a business associate agreement where applicable, and what access controls, authentication, encryption, audit logs, and breach procedures do you maintain?”
2. 2“Which entity owns the clinical record, billing history, consent evidence, cancellation records, and patient messages?”
3. 3“What export format will I receive for those records, and how long will exports remain available after termination?”

Commercial operations

1. 1“Who is the merchant of record for recurring charges, refunds, disputes, and chargebacks?”
2. 2“How are clinical fees, medication charges, pharmacy charges, shipping, lab charges, and membership fees displayed separately?”
3. 3“Can a customer pause, skip, change timing, or cancel without accidentally canceling an already authorized encounter or shipment?”

Compliance and continuity

1. 1“How do you review drug, disease, outcome, and compounded-product claims, and how will you update workflows when federal or state rules change?”

These questions complement broader questions to ask a telehealth platform vendor before signing.

What red flags should end the evaluation?

Some weaknesses are not minor feature gaps. They indicate that the platform may be unsuitable for a recurring telehealth model.

• The vendor cannot demonstrate a real cancellation flow. If cancellation is handled only through support tickets or hidden behind repeated retention prompts, the commercial workflow deserves rejection.
• The system charges before clinical review with no clear refund path. This can create an avoidable mismatch between a commercial promise and a clinical outcome.
• Automatic refills are described as automatic prescriptions. A recurring schedule cannot replace required clinician authorization.
• The vendor will not identify the pharmacy or compounder. Customers and operators need accurate product and dispensing information.
• The agreement claims ownership of the patient list or blocks usable export. That can leave a brand unable to continue records, service, or compliance operations after termination.
• The vendor controls prescribing, diagnosis, or clinical decisions for a nonclinical brand. Technology and administrative support must not be confused with clinical authority.
• Marketing copy suggests compounded products are FDA-approved, identical to, or generic versions of other products. FDA’s 2026 enforcement announcement makes this a material review issue.
• The platform cannot route by patient state or encounter modality. A national storefront cannot safely rely on one eligibility and consent path.
• Pricing, renewal, notice, or exclusivity terms are vague. Unclear commercial terms become especially consequential when the platform controls recurring billing and patient communications.
• Analytics and advertising tools receive clinical information without a clear data map. The buyer needs to know which data flows to subprocessors and whether marketing use can be disabled.

Commercial terms buyers often miss

Feature demonstrations rarely show the contract provisions that determine what happens when the relationship changes. Review these terms before treating a vendor as launch-ready.

Patient-data ownership and export. Define whether the brand, clinical entity, or vendor controls each category of information. Ask for the actual export schema—not merely a promise that data is “portable”—and include clinical records, billing events, consent, subscription history, cancellation confirmations, messages, and audit logs.

Termination and the patient list. Determine what happens to the patient relationship, active subscriptions, pending refills, records, refunds, and customer communications after termination. Identify the export window and whether the vendor continues to charge or message customers during transition.

Notice and renewal. Check automatic contract renewal, termination notice periods, cure periods, service suspension rights, and what happens during a dispute. A short storefront launch timeline does not justify overlooking a long contractual exit.

Exclusivity and non-compete language. Make sure the agreement does not restrict the brand from operating another storefront, engaging another technology provider, or continuing its clinical and pharmacy relationships more broadly than the business intends.

Pricing changes. Ask how much notice applies to platform fees, transaction charges, integrations, support, and other recurring amounts. Also ask whether the vendor can change included functionality at renewal.

Merchant of record. Confirm who collects the customer’s money, issues refunds, handles chargebacks, stores payment data, and communicates billing terms. This role should be consistent with the storefront’s disclosures and the operating agreement.

For contract-specific diligence, pair the scorecard with this guide to telehealth platform contract terms.

A final buyer’s checklist

Before selecting telehealth subscription software, require a written answer or test result for each item:

• Custom domain, mobile storefront, service pages, disclosures, and analytics controls.
• Clear recurring price, interval, fees, consent capture, renewal notice, and cancellation confirmation.
• Pause, skip, timing, failed-payment, refund, and pre-fulfillment cancellation workflows.
• Human clinical review for initial care and refills.
• Patient-location capture, provider-license routing, state-specific consent, and modality controls.
• Pharmacy or compounder identification and accurate product-status language.
• BAA assessment, role-based access, authentication, encryption, audit logs, and subprocessor disclosure.
• Export of clinical, billing, subscription, consent, message, and cancellation records.
• Clear ownership, termination, patient-list, notice, exclusivity, pricing-change, and merchant-of-record provisions.
• A documented response to federal and state rule changes, including the December 31, 2026 controlled-substance telemedicine deadline.

MDLaunchr is one option for a branded telehealth operation, but the right decision depends on evidence against your own workflow, entity structure, clinical model, and customer journey. When you are ready to compare those criteria across platform conversations, compare white-label telehealth platform options for your medical business.